Two-tier subclassification of the Bethesda category III (atypia of undetermined significance/follicular lesion of undetermined significance) in thyroid cytology.
architectural atypia
atypia of undetermined significance/follicular lesion of undetermined significance
nuclear atypia
rick of malignancy
thyroid nodule
Journal
Diagnostic cytopathology
ISSN: 1097-0339
Titre abrégé: Diagn Cytopathol
Pays: United States
ID NLM: 8506895
Informations de publication
Date de publication:
14 Dec 2023
14 Dec 2023
Historique:
revised:
31
10
2023
received:
15
09
2023
accepted:
24
11
2023
medline:
14
12
2023
pubmed:
14
12
2023
entrez:
14
12
2023
Statut:
aheadofprint
Résumé
The Bethesda category III, AUS/FLUS, comprises a heterogeneous group of thyroid lesions with variable risk of malignancy (ROM). This study evaluates ROM in two subgroups of this category based on nuclear atypia and architectural atypia. Cases in Bethesda category III were reported based on nuclear atypia (AUS) and architectural atypia (FLUS). ROM was calculated by comparing the cytologic diagnosis to the follow-up histologic diagnosis. Among the 610 Bethesda category III cases in this study, 306 (50.2%) and 304 (49.8%) cases were reported as AUS and FLUS, respectively. One hundred and eighty six of 306 AUS (60.8%) and 193 of 304 FLUS (63.5%) cases underwent surgical intervention. ROM of the cases in Bethesda category III was 12.8% if all cases were counted and 20.6% if only surgical cases were counted. When analyzing separately, ROM of AUS cases was 17.0% and 28.0% with all cases and surgical cases only, respectively. For FLUS cases, ROM was 8.6% and 13.5% with all cases and surgical cases only, respectively. In Bethesda category III, ROM in the cases with nuclear atypia was significantly higher than the cases with architectural atypia. Sub-classifying the Bethesda Category III cases with nuclear atypia and architectural atypia, respectively may better stratify the ROM.
Sections du résumé
BACKGROUND
BACKGROUND
The Bethesda category III, AUS/FLUS, comprises a heterogeneous group of thyroid lesions with variable risk of malignancy (ROM). This study evaluates ROM in two subgroups of this category based on nuclear atypia and architectural atypia.
METHODS
METHODS
Cases in Bethesda category III were reported based on nuclear atypia (AUS) and architectural atypia (FLUS). ROM was calculated by comparing the cytologic diagnosis to the follow-up histologic diagnosis.
RESULTS
RESULTS
Among the 610 Bethesda category III cases in this study, 306 (50.2%) and 304 (49.8%) cases were reported as AUS and FLUS, respectively. One hundred and eighty six of 306 AUS (60.8%) and 193 of 304 FLUS (63.5%) cases underwent surgical intervention. ROM of the cases in Bethesda category III was 12.8% if all cases were counted and 20.6% if only surgical cases were counted. When analyzing separately, ROM of AUS cases was 17.0% and 28.0% with all cases and surgical cases only, respectively. For FLUS cases, ROM was 8.6% and 13.5% with all cases and surgical cases only, respectively.
CONCLUSION
CONCLUSIONS
In Bethesda category III, ROM in the cases with nuclear atypia was significantly higher than the cases with architectural atypia. Sub-classifying the Bethesda Category III cases with nuclear atypia and architectural atypia, respectively may better stratify the ROM.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Dean DS, Gharib H. Epidemiology of thyroid nodules. Best Pract Res Clin Endocrinol Metab. 2008;22(6):901-911.
Guth S, Theune U, Aberle J, Galach A, Bamberger CM. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest. 2009;39(8):699-706.
Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol. 2008;36(6):425-437.
Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Thyroid. 2009;19(11):1159-1165.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1-133.
Gharib H, Papini E, Valcavi R, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules - 2016 update. Endocr Pract. 2016;22(5):622-639.
Horne MJ, Chhieng DC, Theoharis C, et al. Thyroid follicular lesion of undetermined significance: evaluation of the risk of malignancy using the two-tier sub-classification. Diagn Cytopathol. 2012;40(5):5-410.
Chen JC, Pace SC, Khiyami A, McHenry CR. Should atypia of undetermined significance be subclassified to better estimate risk of thyroid cancer? Am J Surg. 2014;207(3):331-336; discussion 335-6.
Hyeon J, Ahn S, Shin JH, Oh YL. The prediction of malignant risk in the category “atypia of undetermined significance/follicular lesion of undetermined significance” of the Bethesda system for reporting thyroid cytopathology using subcategorization and BRAF mutation results. Cancer Cytopathol. 2014;122(5):368-376.
Walts AE, Bose S, Fan X, et al. A simplified Bethesda system for reporting thyroid cytopathology using only four categories improves intra- and inter-observer diagnostic agreement and provides non-overlapping estimates of malignancy risks. Diagn Cytopathol. 2012;40(suppl 1):E62-E68.
Straccia P, Rossi ED, Bizzarro T, et al. A meta-analytic review of the Bethesda system for reporting thyroid cytopathology: has the rate of malignancy in indeterminate lesions been underestimated? Cancer Cytopathol. 2015;123(12):713-722.
Gan TR, Nga ME, Lum JHY, et al. Thyroid cytology-nuclear versus architectural atypia within the “atypia of undetermined significance/follicular lesion of undetermined significance” Bethesda category have significantly different rates of malignancy. Cancer Cytopathol. 2017;125(4):245-256.
Johnson DN, Cavallo AB, Uraizee I, et al. A proposal for separation of nuclear atypia and architectural atypia in Bethesda category III (AUS/FLUS) based on differing rates of thyroid malignancy. Am J Clin Pathol. 2019;151(1):86-94.
Valderrabano P, Khazai L, Thompson ZJ, et al. Cancer risk associated with nuclear atypia in cytologically indeterminate thyroid nodules: a systematic review and meta-analysis. Thyroid. 2018;28(2):210-219.
Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid. 2017;27(11):1341-1346.
Ali SZ, VanderLaan PA. The Bethesda System for Reporting Thyroid Cytopathology: Definitions, Criteria, and Explanatory Notes. ed. Ali SZ. Springer; 2023.
Siddiqui MA, Griffith KA, Michael CW, Pu RT. Nodule heterogeneity as shown by size differences between the targeted nodule and the tumor in thyroidectomy specimen: a cause for a false-negative diagnosis of papillary thyroid carcinoma on fine-needle aspiration. Cancer. 2008;114(1):27-33.
Baloch Z, LiVolsi VA. The Bethesda system for reporting thyroid cytology (TBSRTC): from look-backs to look-ahead. Diagn Cytopathol. 2020;48(10):862-866.
Bongiovanni M, Papadakis GE, Rouiller N, et al. The Bethesda system for reporting thyroid cytopathology explained for practitioners: frequently asked questions. Thyroid. 2018;28(5):556-565.
Sauter JL, Lehrke H, Zhang X, et al. Assessment of the Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol. 2019;152(4):502-511.
Kim TH, Krane JF. The evolution of “atypia” in thyroid fine-needle aspiration specimens. Diagn Cytopathol. 2022;50(4):146-153.
Olson MT, Clark DP, Erozan YS, Ali SZ. Spectrum of risk of malignancy in subcategories of atypia of undetermined significance. Acta Cytol. 2011;55(6):518-525.
Rosario PW, Calsolari MR. Importance of cytological subclassification of thyroid nodules with Bethesda category III cytology (AUS/FLUS) into architectural atypia only and nuclear atypia: A prospective study. Diagn Cytopathol. 2017;45(7):604-607.
García PL, Surralles ML, Morlius X, Garcia CL, González MC. Prevalence and malignancy of Bethesda category III cytologies of thyroid noddules assigned to the “cytological atypia” and “architectural atypia” groups. Endocrinol Diabetes Nutr. 2018;65(10):577-583.
Deftereos G, Schmechel SC, Waner EE, Itani M, Dighe MK, Tylee, TS. Differential outcomes of patients with thyroid FNA diagnoses of AUS/FLUS with and without nuclear atypia: The potential need for separation in the Bethesda System. Diagn Cytopathol. 2020;48(7):610-617.
Cherella CE, Hollowell ML, Smith JR, et al. Subtype of atypia on cytology and risk of malignancy in pediatric thyroid nodules. Cancer Cytopathol. 2022;130:330-335.
Zhao H, Guo HQ, Zhao LL, et al. Subclassification of the Bethesda category III (AUS/FLUS): a study of thyroid FNA cytology based on ThinPrep slides from the National Cancer Center in China. Cancer Cytopathol. 2021;129(8):642-648.
Guleria P, Agarwal S, Iyer VK, Jain D, Mathur SR, Yadav D. Subcategorisation of AUS/FLUS thyroid lesions as per the 2017 Bethesda system for reporting thyroid cytopathology: a retrospective study from a tertiary care centre analysing risk of malignancy (ROM) of the different subcategories. J Clin Pathol. 2019;72(11):771-777.
Kim SJ, Roh J, Baek JH, et al. Risk of malignancy according to sub-classification of the atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) category in the Bethesda system for reporting thyroid cytopathology. Cytopathology. 2017;28(1):65-73.
Crescenzi A, Palermo A, Trimboli P. Cancer prevalence in the subcategories of the indeterminate class III (AUS/FLUS) of the Bethesda system for thyroid cytology: a meta-analysis. J Endocrinol Invest. 2021;44(7):1343-1351.
Ali SZ, Cibas ES. The Bethesda system for reporting thyroid cytopathology. Definitions, Criteria, and Explanatory Notes. 2nd ed. Wiley; 2017.
Bellevicine C, Sgariglia R, Migliatico I, et al. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations. Cancer Cytopathol. 2018;126(5):317-325.
Baca SC, Wong KS, Strickland KC, et al. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes. Cancer Cytopathol. 2017;125(5):313-322.
Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2(8):1023-1029.
Ohori NP, Wolfe J, Carty SE, et al. The influence of the noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) resection diagnosis on the false-positive thyroid cytology rate relates to quality assurance thresholds and the application of NIFTP criteria. Cancer Cytopathol. 2017;125(9):692-700.
Bongiovanni M, Faquin WC, Giovanella L, Durante C, Kopp P, Trimboli P. Impact of non-invasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP) on risk of malignancy in patients undergoing lobectomy/thyroidectomy for suspected malignancy or malignant fine-needle aspiration cytology findings: a systematic review and meta-analysis. Eur J Endocrinol. 2019;181(4):389-396.
Zhou H, Baloch ZW, Nayar R, et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): implications for the risk of malignancy (ROM) in the Bethesda system for reporting thyroid cytopathology (TBSRTC). Cancer Cytopathol. 2018;126(1):20-26.
Haaga E, Kalfert D, Ludvíková M, Kholová I. Non-invasive follicular thyroid neoplasm with papillary-like nuclear features is not a cytological diagnosis, but it influences cytological diagnosis outcomes: a systematic review and meta-analysis. Acta Cytol. 2022;66(2):85-105.
Ruanpeng D, Cheungpasitporn W, Thongprayoon C, Hennessey JV, Shrestha RT. Systematic review and meta-analysis of the impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) on cytological diagnosis and thyroid cancer prevalence. Endocr Pathol. 2019;30(3):189-200.
Livhits MJ, Zhu CY, Kuo EJ, et al. Effectiveness of molecular testing techniques for diagnosis of indeterminate thyroid nodules. JAMA Oncol. 2021;7(1):70-77.